These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 606410)

  • 1. Prophylactic 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients.
    Walker GS; Peacock M; Aaron J; Robinson PJ; Davison AM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():125s-130s. PubMed ID: 606410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of plasma phosphate on the action of 1alphaOHD3 in haemodialysis patients.
    Peacock M; Davison AM; Walker GS
    Adv Exp Med Biol; 1977; 81():559-69. PubMed ID: 899940
    [No Abstract]   [Full Text] [Related]  

  • 3. Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1alpha-hydroxyvitamin D3.
    Peacock M; Aaron JE; Walker GS; Davison AM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():73s-81s. PubMed ID: 606428
    [No Abstract]   [Full Text] [Related]  

  • 4. Correlation of clinical, biochemical and skeletal responses to 1alpha-hydroxyvitamin D3 in renal bone disease.
    Kanis JA; Earnshaw M; Henderson RG; Heynen G; Ledingham JG; Naik RB; Oliver DO; Russell RG; Smith R; Wilkinson RH; Woods CG
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():45s-50s. PubMed ID: 606424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone disease in children with chronic renal failure: therapy with 1alpha-hydroxyvitamin D3.
    Postlethwaite RJ; Houston IB
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():117s-124s. PubMed ID: 304772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease.
    Kanis JA; Russell RG; Naik RB; Earnshaw M; Smith R; Heynen G; Woods CG
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():51s-57s. PubMed ID: 606425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphate and 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients.
    Davison AM; Peacock M; Walker GS; Marshall DH; McLaughlin MS; Robinson PJ
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():91s-99s. PubMed ID: 606431
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of 1,25(OH)2-vitamin D3 in prevention of renal osteodystrophy: preliminary observations.
    Baker LR; Muir JW; Cattell WR; Tucker KA; Sharman VL; Goodwin FJ; Marsh FP; Hately W; Morgan AG; de Saintonge DM
    Contrib Nephrol; 1980; 18():147-51. PubMed ID: 7353373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 1alpha-hydroxyvitamin D3 on serum calcium and immunoreactive parathyroid hormone in patients with chronic renal insufficiency.
    Pietrek J; Kokot F; Kuska J
    Int Urol Nephrol; 1978; 10(2):153-60. PubMed ID: 700946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease.
    Pierides AM; Ellis HA; Simpson W; Cook D; Kerr DN
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():109s-116s. PubMed ID: 606409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of 1alpha-hydroxyvitamin D3 on calcium and mineral content of bone in renal osteodystrophy.
    Junor BJ; Catto GR
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():131s-138s. PubMed ID: 606411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,25-dihydroxycholecalciferol in patients with chronic renal failure.
    Henderson RG; Ledingham JG; Norman AW; Oliver DO; Preston C; Russell RG; Small DG; Smith R; Warner GT; Woods CG
    Proc Eur Dial Transplant Assoc; 1973; 10(0):202-9. PubMed ID: 4802654
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of 25-hydroxycholecalciferol on calcium metabolism in chronic renal failure.
    Letteri JM; Kleinman LM; Ellis KN; Caselnova R; Akhtar M; Cohn SH
    Adv Exp Med Biol; 1977; 81():591-601. PubMed ID: 899943
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
    Winney RJ; Bone JM; Anderson TJ; Robson JS
    Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593
    [No Abstract]   [Full Text] [Related]  

  • 16. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
    Madsen S
    Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
    [No Abstract]   [Full Text] [Related]  

  • 17. Iliac bone marrow mast cells in relation to the renal osteodystrophy of patients treated by haemodialysis.
    Ellis HA; Peart KM
    J Clin Pathol; 1976 Jun; 29(6):502-16. PubMed ID: 939806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone histomorphometry in patients with chronic renal failure: effect of 1alpha-hydroxyvitamin D3.
    Melsen F; Nielsen HE; Christensen MS
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():39s-44s. PubMed ID: 606423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia.
    O'Donovan R; Baldwin D; Hammer M; Moniz C; Parsons V
    Lancet; 1986 Apr; 1(8486):880-2. PubMed ID: 2870354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis.
    Ellis HA; Pierides AM; Feest TG; Ward MK; Kerr DN
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():31s-38s. PubMed ID: 606422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.